Anbio Biotechnology Class Stock Today
| NNNN Stock | 39.98 11.52 22.37% |
PerformanceStrong
| Odds Of DistressLow
|
Anbio Biotechnology is selling at 39.98 as of the 23rd of July 2025; that is 22.37 percent down since the beginning of the trading day. The stock's open price was 51.5. Anbio Biotechnology has only a 7 % chance of going through financial distress over the next few years and had a strong performance during the last 90 days. The performance scores are derived for the period starting the 24th of April 2025 and ending today, the 23rd of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of February 2025 | Category Healthcare | Classification Health Care |
Anbio Biotechnology is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 43.89 M outstanding shares of which 215.71 K shares are now shorted by private and institutional investors with about 1.0 trading days to cover. More on Anbio Biotechnology Class
Moving together with Anbio Stock
Moving against Anbio Stock
| 0.57 | BCH | Banco De Chile Earnings Call This Week | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Anbio Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anbio Biotechnology Class (NNNN) is traded on NASDAQ Exchange in USA. It is located in Wilhelm Gutbrod Str 21B, Frankfurt am Main, Germany, 60437 and employs 27 people. Anbio Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.32 B. Anbio Biotechnology Class conducts business under Biotechnology sector and is part of Health Care industry. The entity has 43.89 M outstanding shares of which 215.71 K shares are now shorted by private and institutional investors with about 1.0 trading days to cover.
Anbio Biotechnology generates positive cash flow from operations, but has no cash available
Check Anbio Biotechnology Probability Of Bankruptcy
Ownership AllocationAnbio Biotechnology holds a total of 43.89 Million outstanding shares. Anbio Biotechnology Class shows 4.78 percent of its outstanding shares held by insiders and 4.93 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Anbio Ownership Details
Anbio Biotechnology Historical Income Statement
Anbio Stock Against Markets
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Anbio Biotechnology Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anbio Biotechnology. If investors know Anbio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anbio Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.06 | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
The market value of Anbio Biotechnology Class is measured differently than its book value, which is the value of Anbio that is recorded on the company's balance sheet. Investors also form their own opinion of Anbio Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Anbio Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anbio Biotechnology's market value can be influenced by many factors that don't directly affect Anbio Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anbio Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anbio Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anbio Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.